Initiation of antiretroviral treatment with dual nucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected infants with less advanced disease in a resource-limited setting: A Multi-Center Study in Thailand 1998-2000

Journal of the Medical Association of Thailand

Volumn 88, Issue SUPPL. 8, 2005, Pages

  Chokephaibulkit, Kulkanya ^a   Vanprapar, Nirun ^a   Sutthent, Ruengpung ^a   Phongsamart, Wanatpreeya ^a   Chotpitayasunondh, Tawee ^b   Bowornkitikajorn, Piyaporn ^c   Samkoset, Rudeevilai ^d   Tarunothai, Uraiwan ^e   Chearskul, Sanay ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^c Charoen Krung Pracharak Hospital   (Thailand)

^d Phramongkutklo Hospital

^e Vachira Bhayabarn Hospital

Author keywords

Antiretroviral therapy; Dual NRTI; Hiv infected infants

Indexed keywords

DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CHILD DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; THAILAND; TREATMENT OUTCOME; VOMITING;

DEVELOPING COUNTRIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LAMIVUDINE; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 31744440372     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ,et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr 1998; 133: 500-8.
2. Englund JA, Baker CJ, Raskino C,Mckinney RE, Petrie B, Fowler MG,et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 1997; 336: 1704-12.
3. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sex PE, Kalams SA,et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278: 1447-50.
4. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O et al. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997; 175: 1051-5.
5. Hoen B, Dumon B, Harzic M, Venet A, Dubeaux B, Lascoux C, et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. J Infect Dis 1999; 180: 1342-6.
6. Luzuriaga K, McManus M, Catalina M,Mayack S,Sharkey M, Stevenson M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000; 74: 6984-91.
7. Cohen Stuart JW, Slieker WA, Rijkers GT, Noest A, Boucher CA, Suur MH, et al. Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections. AIDS 1998; 12: 2155-9.
8. Gibb DM, Newberry A, Klein N, de Rossi A, Grosch-Woerner l, Babiker A, et al. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet 2000; 355: 1331-2.
9. Spira R, Lepage P, Msellati P, Van De Perre P, leroy V, Simonon A, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics 1999; 104: e56.
10. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997; 336: 1337-42.
11. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998; 279: 756-61.
12. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000; 284: 190-7.
13. Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 2000; 283: 492-8.
14. Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R, et al. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999; 180: 320-9.
15. Berrey MM, Schacker T, Collier AC, Shea T, Brodie SJ, Mayers D, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001; 183: 1466-75.
16. Abrams EJ, Wiener J, Carter R, Kuhn L, Palumbo P,Nesheim S, et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 2003; 17: 867-77.
17. Hainaut M, Ducarme M, Schandene L, Peltier CA, Marissens D, Zissis G, et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2003; 22: 62-9.
18. Yogev R, Lee S, Wiznia A, Nachman S, Stanley K, Pelton S, et al. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. Pediatr Infect Dis J 2002; 21: 119-25.
19. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336: 1343-9.
20. Solder B, Wintergerst U, Notheis G, Eberle J, Gurtler L, Belohradsky BH, et al. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus. J Pediatr 1997; 130: 293-9.
21. Tovo PA, de Martino M, Gabiano C, Cappello N, D'Elia R, Loy A, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. Lancet 1992; 339: 1249-53.